Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Zakay Law Group, APLC and JCL Law Firm, APC, File A Class Action Lawsuit Against Public Health Institute, Alleging Failure to Provide Compliant Meal and Rest Breaks


If you would like to know more about the Public Health Institute lawsuit, please contact Attorney Jackland Hom today by calling (619) 255-9047.

The Northern California labor law attorneys, at Zakay Law Group, APLC and JCL Law Firm, APC, filed a class action complaint against Public Health Institute for allegedly failing to accurately pay employees’ wages for all their time worked. The Public Health Institute class action lawsuit, Case No. 23CV028034, is currently pending in the Alameda County Superior Court of the State of California. A copy of the Complaint can be read here.

According to the lawsuit, Public Health Institute allegedly violated California Labor Code Sections §§ 201, 202, 203, 204, 210, 226.7, 510, 512, 558, 1194, 1197, 1197.1, 1198, and 2802 by failing to: (1) pay minimum wages; (2) pay overtime wages; (3) provide required meal and rest periods; (4) pay wages when due; (5) provide accurate itemized wage statements; and (6) reimburse for required business expenses

California Labor Code Section 226 requires an employer to furnish its employees an accurate itemized wage statement in writing showing (1) gross wages earned, (2) total hours worked, (3) the number of piece-rate units earned and any applicable piece-rate, (4) all deductions, (5) net wages earned, (6) the inclusive dates of the period for which the employee is paid, (7) the name of the employee and only the last four digits of the employee’s social security number or an employee identification number other than a social security number, (8) the name and address of the legal entity that is the employer and, (9) all applicable hourly rates in effect during the pay period and the corresponding number of hours worked at each hourly rate by the employee. Public Health Institute allegedly failed to provide its employees with accurate itemized wage statements that complied with all the requirements of California Labor Code Section 226.

If you would like to know more about the Public Health Institute lawsuit, please contact Attorney Jackland Hom today by calling (619) 255-9047.

Zakay Law Group, APLC and JCL Law Firm, APC are labor and employment law firms with offices located in California that dedicate their practices to fighting for employees who have been wronged by their employers due to unfair employment practices. Contact one of their attorneys today if you need help with workplace issues regarding wage and hour, wrongful termination, retaliation, discrimination, and harassment.

-THIS IS AN ATTORNEY ADVERTISEMENT-

Share article on social media or email:

Upneeq® Wins “Best Eye Drop for Drooping Lids” New Beauty In 13th Annual Beauty Awards


Upneeq®, 2023 New Beauty award winner for “Best Eyedrop for Drooping Lids”

“Upneeq has proven to be a gamechanger in our field,“ said Dr. Raymond Douglas, board certified occuloplastic surgeon and Director, Thyroid Eye Disease Center at Cedars Sinai. “It can work in one or both eyes in as little as five minutes giving the eyes a wider, and brighter appearance.”

RVL Pharmaceuticals announced today that its prescription eye drop Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected the winner in the professional treatment category as “Best Eye Drop for Drooping Lids” in the NewBeauty 13th Annual Beauty Awards. Upneeq is FDA approved for the treatment of acquired blepharoptosis (droopy eyelids) in adults. It is the second consecutive win for the brand. Upneeq® was awarded the “Best Innovation” in 2022 by this definitive authority in beauty. The 13th Annual NewBeauty Awards issue hits newsstands on April 4, 2023.

Over 10,000 products were submitted for the 2023 awards with 399 selected. Each winning product was proven to both effectively solve an aesthetic concern and meet rigorous testing standards by the NewBeauty editorial team along with an independent panel of key opinion leaders, top medical and industry professionals as well as advisors.

According to NewBeauty Features Editor, Tatiana Bido “Upneeq couldn’t be any easier to use.” She also called it an instant eyelid-lifter for ptosis or low-lying lids during their testing process.

“Upneeq has proven to be a gamechanger in our field,“ said Dr. Raymond Douglas, M.D., PhD, a board-certified Aesthetic Reconstructive and Oculoplastic Specialist and Global Head of Scientific Affairs for RVL Pharmaceuticals. “It can work in one or both ptotic eyes in as little as five minutes giving the eyes a more open looking appearance. With the drop we see an average eyelid elevation between 1 and 2 millimeters which is truly significant.”

“We are incredibly proud to be acknowledged for a second year by NewBeauty with this prestigious award”, said Brian Markison, Chief Executive Officer of RVL Pharmaceuticals. “We are building a new market where Upneeq has been an exciting innovation for eyelids – as the first Rx treatment for low-lying lids in adults. As we continue to build the brand in the medical aesthetics field, this recognition from the industry’s leading authority is compelling and beneficial validation.”

Upneeq® received FDA approval in July 2020 and was introduced as the only non-surgical therapeutic approved for acquired ptosis (low-lying lids) in adults. First-in-class, Upneeq® is a safe and effective, fast acting, daily treatment for patients at eye care and medical aesthetic practices nationally.

In clinical trials, Upneeq® demonstrated statistically significant improvements compared to placebo in both superior visual field and eyelid lift, as measured in two pivotal double-masked efficacy studies. The most common adverse reactions with Upneeq (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache. For more information and for the complete Important Safety Information, visit http://www.upneeq.com

IMPORTANT SAFETY INFORMATION

What is UPNEEQ?

UPNEEQ ® (oxymetazoline hydrochloride ophthalmic solution), 0.1% is a prescription eyedrop used to treat acquired blepharoptosis (low-lying lids) in adults.

What warnings and precautions are associated with UPNEEQ?

  • Low-lying lids may be related to conditions such as stroke and/or brain aneurysm, Horner syndrome, myasthenia gravis, loss of the ability to move eye muscles, eye infection and eye tumors. Tell your doctor if you have any of these conditions.
  • UPNEEQ is a type of medication that may affect your blood pressure. If you have heart disease, uncontrolled high or low blood pressure, or feel faint at rest or when quickly standing up, you should call your doctor if your symptoms get worse.
  • Patients with reduced blood flow to the brain or heart, or patients who experience eye or mouth dryness due to an immune system disorder (Sjögren’s syndrome), should use care when taking UPNEEQ. Call your doctor immediately if you feel your symptoms may be getting worse.
  • UPNEEQ may increase the risk of eye pressure due to fluid buildup (angle-closure glaucoma) in patients with untreated narrow-angle glaucoma. Call your doctor immediately if you feel increased pressure in your eye after using UPNEEQ.
  • Do not let the tip of the UPNEEQ vial touch your eye or any other surface. This can help prevent eye injury or contamination. Each UPNEEQ vial is for one-time use and should be discarded after being used.

What are the most common side effects of UPNEEQ?

  • The most common adverse reactions with UPNEEQ (occurring in 1-5% of patients) were eye inflammation, eye redness, dry eye, blurred vision, eye pain at time of use, eye irritation, and headache.

What should my doctor know about before prescribing me UPNEEQ?

  • Your doctor should review your full medical history before prescribing UPNEEQ.
  • UPNEEQ belongs to a class of medication (alpha-adrenergic agonists) that may affect your blood pressure. Use UPNEEQ carefully if you currently take an alpha-adrenergic agonist medication to treat heart disease or an enlarged prostate. Patients taking beta-blockers, or other medications to treat hypertension or an abnormal heartbeat, should also be careful when using UPNEEQ.
  • Patients who use a certain class of antidepressant medication (monoamine oxidase inhibitors) should also be careful when using UPNEEQ, as it may affect the way your body absorbs the medication.

These are not all of the possible side effects of UPNEEQ. Tell your doctor if you have any side effect that bothers you or does not go away. Call your doctor for medical advice about side effects.

To report side effects or product complaints, contact RVL Pharmaceuticals at 1-877-482-3788. You may also report side effects to the FDA by calling 1-800-FDA-1088 or visit http://www.fda.gov/medwatch.

This is a summary of the most important safety information for UPNEEQ. For more in-depth safety information, please review the full Prescribing Information for UPNEEQ.

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.

About NewBeauty / NewBeauty Awards

The highly regarded industry and consumer publication, NewBeauty is published by Sandow Media. NewBeauty is the ultimate resource redefining the beauty space with its trend-driven approach to content combining authoritative experts, education and advances in industry innovation. Filled with NewBeauty editors’ trusted voices, the magazine provides an in-depth and comprehensive look at new products and breakthrough technologies with a split reputation of scientifically accurate expert-driven original reporting with ethically balanced editorial resources. NewBeauty offers a highly- curated group of winners in the annual NewBeauty Awards. Product winners of the NewBeauty Awards Seal must effectively deliver on their claims, solve aesthetic concerns, and fulfill the rigorous testing process of editors and experts.

Share article on social media or email:

MedSpeed Announces “25 by 25” Electric Vehicle Commitment


News Image

Health isn’t just what happens in a doctor’s office or hospital, it’s about the environment around us and everything people need to live healthy lives. This commitment to the electrification of our fleet reflects our company values.

MedSpeed, the market-leading provider of same-day transportation services to the healthcare industry, announced its new electric vehicle initiative, “25 by 25.” The company has committed to convert 25 percent of its current eligible fleet to electric vehicles by the end of 2025.

“Health isn’t just what happens in a doctor’s office or hospital, it’s about the environment around us and everything people need to live healthy lives,” said Jake Crampton, CEO of MedSpeed. “MedSpeed has made a concerted effort to contribute to the health of our communities by reducing the number of miles driven, digitizing paper processes and helping our customers reduce waste. This commitment to the electrification of our fleet reflects our company values and we are super excited to take that forward.”

In 2022, MedSpeed partnered with the General Motors fleet team to begin its electrification efforts. After evaluating the electric vehicle options, MedSpeed placed an initial order for 50 Chevy Bolts. Placing this order was a first strong step toward meeting the company’s “25 by 25” pledge, as the order made up more than one-third of MedSpeed’s eligible vehicle replacements.

“Each of the Bolt EVs we’ve placed in operation in California is equivalent to the annual atmospheric cleaning power of 375 mature trees,” said Natalie Laackman, MedSpeed CFO. “As MedSpeed continues to add EVs into our fleet, we are making a cleaner environment for the future, reducing operational costs and contributing to a better way of life in the communities where we operate.”

In addition to its electric vehicle initiative, MedSpeed continues to contribute to sustainability in other ways.

  • Smart network design — MedSpeed’s smart network design process reduces the number of miles driven by an average of 25 percent per customer
  • Reduce redundant transportation — MedSpeed reduces redundant transportation (and other shipping) by consolidating other movements into its customers’ existing routes
  • Waste avoidance — MedSpeed’s customers avoid waste from product expiration by sharing items through the connected network
  • Paperless to digital — MedSpeed has a digital ecosystem that reduces paper consumption through paperless invoicing as well as paperless activity logging and reporting
  • Quality — MedSpeed’s leading quality rating leads to fewer unnecessary miles driven to correct errors

“Sustainability is something we all own,” continued Laackman. “It’s important that as a business and as leaders, we champion making a difference through authentic change. We see this as a first step in our ongoing journey.”

To celebrate the first electric vehicles the company added to its fleet, in mid-January MedSpeed held an event at its San Diego hub, which has been outfitted with charging stations. The company will be adding charging stations for its expanded fleet to several other hubs around the U.S. later this year.

About MedSpeed

MedSpeed integrates healthcare organizations through the enterprise-wide movement of physical materials: specimens, pharmaceuticals, supplies and more. It transforms transportation into a strategic asset that more effectively utilizes scale, reduces risk, eliminates redundancies and centralizes services. The company has grown from a Chicago-based startup into a national enterprise with over 150 hub operations across 32 states. Its client base includes 29 of the top 100 health systems in the country. http://www.medspeed.com

Share article on social media or email:

Sensate Raises $3.2M Seed Round on a Mission to Reduce the Effects of Stress and Expand Access to Wellness, Worldwide


Lower stress and anxiety with Sensate

“Millions of people are seeking an easy way to feel less stressed and anxious and we’ve seen increasing demand for our product. In the second half of 2022 we grew almost 300% and this round will allow us to scale and serve even more people,” said Anna Gudmundson, Co-Founder and CEO of Sensate.

Sensate, a wellness technology company that created a patented relaxation device+app turning the tide on stress, announced today that it closed $3.2M in a seed funding round in February, led by Incisive Ventures.

Co-investors in the round include Share Ventures, Geek Ventures, Dangerous Ventures, Unlock Venture Partners, Moai Capital, and 37 Angels. (Important correction: the initial press release included What If Ventures as an investor. We have great admiration for What If Ventures, but we never discussed this round with the fund and the error was a drafting mistake by an external contractor. We apologize for any confusion and thank What If Ventures for their grace and understanding.)

Sensate’s hardware and subscription app innovation uses patented technology designed to activate the body’s natural ability to self-regulate. An incredibly easy, fast, and accessible way to relieve stress, the device was developed by physicians and tested in clinics. Using infrasonic therapy to help the body’s nervous system recover from daily stresses, Sensate’s intelligent touch therapy is entirely effort-free for the user.

A portion of the seed round was raised via Wefunder, the leading retail investment platform for Regulation Crowdfunding. Through Wefunder, the company offered over 900 customers, early supporters and friends, including Hollywood celebrities, the chance to become shareholders in Sensate alongside institutional investors in a seed round via an SPV.

“Millions of people are seeking an easy way to feel less stressed and anxious and we’ve seen increasing demand for our product. In the second half of 2022, we grew almost 300% and this round will allow us to scale and serve even more people,” said Anna Gudmundson, Co-Founder and CEO of Sensate.

Gudmundson’s Co-founder is Sensate innovator and integrated medicine physician, Stefan Chmelik. Chmelik has decades of clinical experience specializing in complex stress and health issues. Gudmundson herself has over 15 years of experience in exponential technologies, and as in previous roles like turnaround CEO, she effectively optimizes and delivers company product, brand and business strategy.

“We’ve been looking for a team and platform focused on the opportunity to explore vagus nerve toning,” stated Hamet Watt, Founder and Managing Partner at Share Ventures, a Los Angeles-based venture foundry and fund. “We’re excited to have found that in Sensate, and are thrilled to support their innovative wellness technology, which has the potential to revolutionize the way people manage stress and anxiety. Sensate’s management and team both bring unique expertise to this field, and we look forward to partnering with them on their mission to promote mental wellness.”

Geek Ventures, an NYC-based VC that invests in immigrant founders building exciting scalable tech, also invested in the round. Ihar Mahaniok, Managing Partner at Geek, added, “I’ve seen firsthand the transformative power of Sensate’s device, and it’s clear that I’m not the only one. The love and loyalty from their users are a testament to the incredible impact they are having on people’s lives. With such a talented team at the helm, I have no doubt that Sensate will continue to innovate and build solutions that make a real difference in the world, and I am glad we can support them in their quest.”

Sensate’s breakthrough technology has been dubbed ‘a genius device’ by Forbes and was honored as a TIME Magazine Best Invention of 2022. Sensate exceeded its 2022 growth targets, with a $10.2M revenue run rate as of December 2022. Sensate is poised to combat the global stress crisis, revolutionizing the exponentially growing $4.2T wellness market.

Companies or Investor Relations firms interested in learning more about Sensate and its mission can visit https://www.getsensate.com/.

About Sensate

Sensate, Inc. is a wellness technology company with a mission to bring stress resilience and well-being to people from all walks of life. Using powerful methods and groundbreaking technology, the company offers patented stress-regulation hardware and software applications for the consumer market. Sensate is a direct-to-consumer business selling globally, with operations in the US and UK. Sensate can be found on http://www.getsensate.com as well as in world-class retailers, including Harrods, Selfridges, Amazon, and has been featured in TIME, Forbes, Vogue, Buzzfeed, BBC Click, Mashable, CNBC, and many more.

Contact: Michelle Laven – Head of Communications

press@getsensate.com

Share article on social media or email:

BCFFR in Boston Named Castle Connolly Top Doctors for 2023


Dr. Leonard Miller, Dr. Melissa Michelon, Dr. Farah Moustafa, and Dr. Sean Doherty, all named to Castle Connolly's top doctors in 2023

Dr. Leonard Miller, Dr. Melissa Michelon, Dr. Farah Moustafa, and Dr. Sean Doherty, all named to Castle Connolly’s top doctors in 2023

We continue to maintain high standards with excellent patient satisfaction and we are honored to have a team full of award-winning physicians.

The elite team of physicians at BCFFR, Leonard B. Miller, MD – Plastic Surgery, Sean T. Doherty, MD – Plastic Surgery, Melissa A. Michelon, MD – Dermatology, and Farah Moustafa, MD – Dermatology, are honored to be listed in Castle Connolly America’s Top Doctors again in 2023 in recognition of their commitment to excellence in medicine and patient care.

Dr. Miller states “We continue to maintain high standards with excellent patient satisfaction and we are honored to have a team full of award-winning physicians.”

Boston Center for Facial Rejuvenation in Boston, MA, is one of the longest-standing medical practices in Boston, offering advanced cosmetic and medicinal treatments. The highly-recognized BCFFR plastic surgeons and award-winning dermatologists collaborate to ensure each patient receives the best treatments, outstanding results, and superb follow-up care.

BCFFR Listed Among Castle Connolly America’s Top Doctors

It is an honor for BCFFR to be listed again among Castle Connolly America’s Top Doctors. 2023 is the 30th anniversary of Castle Connolly Top Doctors, representing the top seven percent of all physicians nationwide. Castle Connolly Top Doctors is a highly respected medical research source featured by multiple reputable media sources, such as Good Housekeeping, Morning News on CNN, and 48 hours on CBS-TV.

Castle Connelly’s peer-nominated and thoroughly vetted physician-led research team selects the best-in-class healthcare providers who embody excellence in clinical care and interpersonal skills. Eligibility of each peer-nominated physician is based on the number of nominations, patient ratings, education, hospital and facility appointments, professional qualifications, research leadership, disciplinary history, interpersonal skills, professional reputation, outcomes data, and more.

BCFFR Recognized for Outstanding Patient Care

The Boston Center for Facial Rejuvenation is recognized repeatedly for its outstanding care of patients and dedication to furthering medical science. In addition to dermatology and cosmetic procedures like tummy tucks and Juvederm injections, BCFFR offers medical dermatology to cover a broad spectrum of skin concerns like acne and rosacea.

The BCFFR plastic surgeons and dermatologists are devoted to providing outstanding care for each patient and advancing technology. Board-certified plastic surgeons Drs. Miller and Doherty are Castle Connolly America’s Top Doctors for 2023, featured in Boston Magazine’s Top Doctors for 2023, and recognized by RealSelf, Vitals, and America’s Best Physicians.

“I am thrilled to be named a Castle Connolly Top Doctor for 2023. It is an honor to again be part of the best-in-class health care providers in the Boston area. This group is nominated based on excellence in patient care. I am proud to represent Plastic Surgery on this list!” states Sean Doherty, MD.

Ground-Breaking Leaders in Technology

The BCFFR Castle Connolly America’s Top Doctors are well-established speakers, trainers, and peer-to-peer educators. They are well-known for natural-looking results from injections and both surgical and non-surgical procedures focusing on incremental improvements without discomfort, swelling, or bruising. The BCFFR physicians embrace innovative technology and were the first facility in the United States to perform microneedling.

Leonard Miller, MD, FACS, founded BCFFR and Advanced Aesthetic Technologies and is devoted to producing and introducing advanced aesthetic products globally. Sean Doherty, MD serves as the medical director and principal investor for Cynosure, Inc. and a Principal Investor in FDA-approved Sculpsure.

The Boston Center for Facial Rejuvenation team of physicians is passionate about bringing new products to the marketplace to address common issues with hyaluronic acid injectables, like delayed adverse events and puffiness. They also have a new non-hyaluronic acid dermal filler currently in FDA trials, planned to be on the US market in 2024.

America’s Top Doctors Offer Definitive Answers

Board-certified plastic surgeons Drs. Miller and Doherty and board-certified dermatologists Drs. Michelon and Moustafa are listed as Castle Connolly America’s Top Doctors because they perform the finest techniques to ensure extraordinary, natural-looking cosmetic results. They feature outstanding technology, including Fraxel laser, microdermabrasion, intense pulse light (IPL), microneedling, radiofrequency microneedling, neurotoxins, dermal fillers, eye lift surgery, natural facelift, liposuction, breast augmentation and breast reduction, male body contouring, gynecomastia, fat transfers and more.

During the consultation, the doctor spends time with each patient to build a professional relationship built on trust and respect. The BCFFR team works together to give patients exceptional care and believe less is often better, preventing scars and an excessive surgical look. They explain the details of the procedure and answer any questions to alleviate anxiety and ensure realistic expectations about the process and recovery.

The Boston Center for Facial Rejuvenation in Boston, MA, utilizes the most efficient techniques and discourages radical or extensive cosmetic procedures. They take a skilled and careful approach, perform the latest methods and use the best practices to avoid complications and provide consistent results. BCFFR has earned a 4.7 star review on Google from satisfied patients.

###

The Boston Center for Facial Rejuvenation in Boston, MA, features the latest innovative techniques to ensure outstanding results with minimal downtime. For more information, please call (617) 735-8735 0070 or visit our website at BCFFR.com.

MatTek and Visikol Announce That Two Companies Merging Into One


Today, MatTek CEO Alex Armento and Visikol CEO Michael Johnson, Ph.D., have announced that the two companies will officially be merging into one company under the MatTek name. Previously, both MatTek and Visikol had been acquired in the first half of 2021 by CELLINK (later renamed BICO) as well as the assets of HUREL which had been incorporated into Visikol. The two companies are both highly focused on advanced cell culture models and assays, where Visikol primarily operates as a contract research services business and MatTek operates predominantly as a products based company. Together, the two companies have the largest offering of advanced cell culture models and services in the marketplace and are helping to shape the future of microphysiological systems.

While both companies operated independently as part of BICO up to this point, there are a multitude of synergies that can be realized by combining the two entities.

“We have been working closely with MatTek prior to both of our acquisitions and we saw this merger as a natural fit to both more easily work together and also to share best practices and resources such that together we can have a more efficient and higher growth company,” described Visikol CEO Dr. Michael Johnson.

As the two companies combine under the MatTek name, the Visikol brand will be maintained and both companies will continue to operate as they have. However, the two company’s core general administrative functions such as finance, marketing, sales and human resources will be combined thus resulting in significant gains in efficiency. After the merger, the MatTek team will have over 100 employees and sites that include Hampton, NJ, Ashland, MA, and Bratislava, Slovakia.

“Our goal as a company has always been to reduce the usage of animals and to help accelerate the discovery and development of new therapeutics and teaming up more formally with the Visikol team allows us to better achieve this mission,” described MatTek CEO Alex Armento.

Following the merger, Visikol CEO Dr. Johnson will take on the role of Chief Commercial Officer for MatTek and will oversee the commercial efforts of MatTek and the legacy Visikol business, while still overseeing the general operations of the Hampton, NJ site that houses the Visikol services and products.

About MatTek

MatTek was founded in 1985 and began producing human tissue models as reliable replacements for animal testing. MatTek’s skin, ocular, oral, respiratory, and intestinal tissue models are used to assess safety and efficacy throughout the pharmaceutical, cosmetics, personal care, and household product industries. These advanced tissue models empower companies to achieve their goals of non-animal testing while lowering testing costs and providing human-relevant results. The company has expanded its offerings to include cultureware, primary human cells and media, kits, and testing services in support of its mission to advance innovative in vitro science through the production of synergistic life science products and services. For more information visit their website, http://www.mattek.com.

About Visikol

Visikol is a contract research services company that is focused on accelerating drug discovery and development through the use of its imaging, digital pathology and advanced cell culture assay services. The company provides end-to-end preclinical services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, multiplex imaging, high content imaging, digital pathology and custom drug discovery solutions. Visikol’s expertise is in transforming tissues and cells into large image-based data sets that can be mined for actionable insights such that pharmaceutical and biotech companies can make more quantitative and informed decision during the drug development process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit http://www.visikol.com.

Share article on social media or email:

Tittle Endodontics Announces New Website and Rebrand, Welcomes Dr. Mia Tittle


Tittle Endodontics, Pleasant Hill, CA

Tittle Endodontics, Pleasant Hill, CA

I look forward to building upon my father’s 30 years of experience and continuing the legacy of excellence he has established.

Tittle Endodontics, a premier endodontic practice located in Pleasant Hill, California, announces the launch of its new website with the addition of a new doctor, Dr. Mia J. Tittle. The practice offers comprehensive and compassionate endodontic care for patients throughout Pleasant Hill, Walnut Creek, Lafayette, Danville, Concord, Benicia, Orinda, and the Bay Area.

Tittle Endodontics’ new website, located at https://www.tittleendo.com, includes information on the practice, its doctors and staff, as well as patient education resources. Visitors to the website will find information about endodontic services and procedures provided, as well as a blog to stay up to date on the latest in endodontic news.

Patients can access a range of resources, including treatment aftercare instructions and previous patient testimonials. The website also provides a link for them to request an appointment online, access new patient forms, and apply for CareCredit financing.

Dr. Mia Tittle joins her father, Dr. Kenneth Tittle, a Board-Certified endodontist, after she worked as a general dentist in the Bay Area. Dr. Mia Tittle graduated from UCSB and completed her Doctorate of Dental Surgery and Endodontics Residency at the University of the Pacific Arthur A. Dugoni School of Dentistry, where she also received her Masters of Science in Dentistry.

“I’m excited to provide patients with the highest quality of dentistry in a comfortable environment,” said Dr. Mia Tittle. “I look forward to building upon my father’s 30 years of experience and continuing the legacy of excellence he has established.”

They are joined by a team of endodontic assistants and office managers who are dedicated to providing patients with the highest quality of care. Dr. Kenneth Tittle, Dr. Mia Tittle, and staff are committed to providing patients with a comfortable, stress-free experience.

Tittle Endodontics is a family-owned and operated practice that has been providing quality endodontic care to patients throughout Pleasant Hill for over 25 years. They are committed to providing patients with state-of-the-art endodontics in a comfortable and friendly environment.

The practice is equipped with the latest endodontic technology, including Cone Beam Computed Tomography, intraoral cameras, and GentleWave irrigation systems. In addition, Tittle Endodontics offers a range of services pertaining to diseases of the pulp and surrounding tissues of a tooth, including:


  • Root canal treatment: Root canal treatment is a procedure that removes inflamed or infected tissue from a diseased, infected, or damaged tooth root.
  • Endodontic retreatment: Endodontic retreatment can be indicated when a tooth with a previous root canal becomes reinfected.
  • Endodontic surgery: Endodontic surgery is used to remove damaged or infected tissue from the tooth root in a surgical manner
  • Dental trauma treatment: Dental trauma treatment can be used to repair a damaged or broken tooth.

About Tittle Endodontics

Tittle Endodontics is a state-of-the-art endodontic practice located at 401 Gregory Lane #118 in Pleasant Hill, California. To make an appointment, call 925-676-3388 or visit Tittle Endodontics at their website, https://www.tittleendo.com, to request an appointment online.

Share article on social media or email:

American College of Lifestyle Medicine’s Health Equity Initiative Expands Priorities to Include Federally Qualified Health Centers


News Image

“With more than 1,400 FQHCs/CHCs in the nation, the impact that the clinicians from these institutions can have on addressing health care disparities is tremendous.”

The American College of Lifestyle Medicine’s (ACLM) HEAL (Health Equity Achieved through Lifestyle Medicine) Initiative announced today an additional strategic priority to continue addressing the needs of historically underserved groups that are at a higher risk for chronic disease. Effective April 1, 2023, HEAL leadership will add a focus on integrating lifestyle medicine into Federally Qualified Health Centers (FQHCs) and Community Health Centers (CHCs).

An important element of this new strategy is ACLM’s 5.5-hour CME/CE-accredited complimentary course, “Introduction to Lifestyle Medicine & Food as Medicine Essentials” course bundle. The course is available, at no cost, to health care providers across the country, including those at FQHCs who typically serve historically medically underserved individuals disproportionately impacted by chronic disease.

“With more than 1,400 FQHCs/CHCs in the nation, the impact that the clinicians from these institutions can have on addressing health care disparities is tremendous,” said ACLM President and Harvard Medical School faculty member Beth Frates, MD, FACLM, DipABLM. “For that reason, ACLM is committed to executing a strategy, designed and developed by HEAL leaders, that will equip FQHC/CHC clinicians with lifestyle medicine education.”

While addressing lifestyle as a first treatment option is the top recommendation in most chronic disease clinical guidelines, providers skip this step because of lack of formal training in nutrition and physical activity, as well as in other lifestyle domains. The free course, as part of ACLM’s White House Conference on Hunger, Nutrition and Health commitment, helps to fill the void of nutrition education that exists in medical and other health professional training.

As HEAL undergoes a leadership transition, also effective April 1, incoming leaders are gearing up to support ACLM in its efforts to offer the Essentials course bundle broadly, especially to those who are serving historically medically underserved patients. Incoming HEAL co-chairs are: David Bowman, MD, DipABLM and Qadira Ali Huff, MD, MPH, FAAP, DipABLM; and incoming HEAL secretary Daphne Bascom, MD, PhD. Dr. Bowman, an ACLM Board of Directors member, is a board-certified lifestyle medicine physician and pediatrician currently on faculty at Howard University College of Medicine’s Pediatric and Child Health Department. Dr. Huff is a board-certified pediatrician, certified lifestyle medicine physician, and clinical assistant professor of pediatrics at George Washington School of Medicine and Health Sciences. She practices at Children’s National Hospital. Dr. Bascom is a certified health coach and a principal health practice and systems engineer consultant with the VA Health, Innovation & Central Office. Each leader has laudable experience and has demonstrated their passion for health equity and lifestyle medicine.

Lifestyle medicine is a medical specialty that uses therapeutic lifestyle interventions as a primary modality to treat chronic conditions including, but not limited to, cardiovascular diseases, type 2 diabetes, and obesity. HEAL mobilizes its member base of health equity advocates from across the country and health care spectrum to share effective ways to reach medically underserved communities with limited-to-no-access to lifestyle medicine and/or health care, food insecurity, and other social determinants of health that impede on their ability to live healthy lifestyles.

The inaugural, outgoing HEAL co-chairs Terri Stone, MD, DipABLM, and Marsha-Gail Davis, MD, DipABLM, and secretary Erin Sinnaeve, DNP, FNP-C, set the foundation for the initiative alongside HEAL founder and former ACLM President Dexter Shurney, MD, MBA, MPH, DipABLM, in 2019. In 2020, ACLM convened some of the nation’s foremost thought leaders at the inaugural Health Disparities Solution Summit to discuss how lifestyle medicine strategies can help bridge the gap between health disparities and the impact on racial and ethnic populations across the country. The recommended action steps were incorporated into HEAL priorities and the work became the HEAL Initiative.

Since its inception, the founding leaders have grown the Initiative to 450 interdisciplinary health team members who meet regularly to discuss practical and tangible ways to equitably treat and empower patients from all backgrounds with the tools they need to lead healthy lives. Another effort of the Initiative, the HEAL Scholarship Program, has provided training funding for underrepresented in medicine (UIM) physicians to diversify the lifestyle provider workforce. Since 2021, the HEAL Scholarship Program has awarded 36 full scholarships to UIM clinicians.

ABOUT ACLM

The American College of Lifestyle Medicine is the nation’s medical professional society advancing lifestyle medicine as the foundation for a redesigned, value-based and equitable healthcare delivery system, leading to whole person health. ACLM educates, equips, empowers and supports its members through quality, evidence- based education, certification and research to identify and eradicate the root cause of chronic disease, with a clinical outcome goal of health restoration as opposed to disease management.

ABOUT HEAL

The American College of Lifestyle Medicine (ACLM) first established the Health Equity Achieved through Lifestyle Medicine (HEAL) Member Interest Group in 2019 to address lifestyle-related chronic disease health disparities. In 2020, ACLM convened some of the nation’s foremost thought leaders at the inaugural Health Disparities Solution Summit to discuss how lifestyle medicine strategies can help bridge the gap between health disparities and the impact on racial and ethnic populations across the country. The recommended action steps were incorporated into HEAL priorities and the work became the HEAL Initiative. Over 450 health equity advocates from a myriad of specialties now connect monthly to discuss unique and effective ways to reach medically underserved communities experiencing health care access issues, food insecurity, and other social determinants of health that impede on their ability to live healthy lifestyles.

Share article on social media or email:

Grand Opening Ribbon Cutting for American Treatment Network Outpatient Drug and Alcohol Treatment Facility at Crozer Health


American Treatment Network

We welcome this opportunity to help serve the people of Delaware County and work closely with Crozer Health, as they continue to support the behavioral health needs of the county.

On Tuesday, April 11th from 10:30am-12:00pm, American Treatment Network will host a Grand Opening Ribbon Cutting Ceremony to formally open its state-of-the-art integrated SUD treatment model on the campus of Crozer-Chester Medical Center, at Suite 207 of Medical Office Building 1 in Upland, PA. Senator John Kane will be in attendance of the grand opening for the new outpatient drug and alcohol center that will provide much-needed services to county residents living with substance abuse disorders and mental health conditions.

In October of 2022, Crozer Health named American Treatment Network as its preferred provider for outpatient drug and alcohol services in Delaware County, PA. Located within the Chester-Crozer medical campus at MOB 1, Suite 207, American Treatment Network will work in conjunction with Crozer Health System by offering outpatient drug and alcohol services as well as acting as a 24/7 Assessment Center for Delaware County. American Treatment Network will act as the primary substance use treatment provider for all Crozer Health emergency rooms and physicians network. By partnering with American Treatment Network, Crozer will be equipped with all the tools needed to treat substance abuse and mental health issues within the community.

Matthew Sullivan, ATN’s co-founder and CEO, stated, “We welcome this opportunity to help serve the people of Delaware County and work closely with Crozer Health, as they continue to support the behavioral health needs of the county.” He continued, “As the largest health system in the county, Crozer Health can continue to lead in the fight to help undo the damage caused by the opioid epidemic in the county.”

About American Treatment Network:

American Treatment Network is a value based, multi-state outpatient substance abuse provider with operations throughout Pennsylvania and Delaware. American Treatment Network was founded to disrupt the current fragmented outpatient addiction treatment landscape by promoting health equity to all who seek outpatient addiction care. For more information, visit http://www.americantreatmentnetwork.com

Share article on social media or email:

New Data Reveals Advantages of Chelamax® Magnesium Citrate for Gummy Formulations


Chelamax® Whitepaper

“This study provides scientific evidence supporting the superior performance of Chelamax® Magnesium Citrate.”

Innophos, a leading international producer of nutritional specialty ingredients and custom-formulated solutions, today announced the release of its latest whitepaper demonstrating the benefits of utilizing Chelamax® Chelated Magnesium Citrate in the formulation of pectin-based gummy supplements.

Gummies are a popular delivery form for dietary supplements, vitamins, and other nutraceuticals. However, gummy production can be challenging due to the complex interactions between the ingredients. With consumer interest in magnesium at all-time highs, dietary supplement manufacturers are focusing on magnesium citrate because it is known for its solubility, bioavailability, and low reactivity, making it an ideal ingredient for gummy production. Yet, manufacturers struggle to make magnesium gummies that set properly, have an appealing texture, and have higher magnesium loads.

In a new study, Innophos evaluated the effect of three different USP sources of magnesium citrate compounds on the texture and stability of pectin-based gummies. The study shows significant advantages of Chelamax® Magnesium Citrate vs. the alternatives. Specifically, pectin gummies made with Chelamax® Magnesium Citrate exhibit:

  • A more pleasing texture
  • Less stickiness
  • Higher loading levels of magnesium

“This study provides scientific evidence supporting the superior performance of Chelamax® Magnesium Citrate,” said Karen Winkowski, Ph.D., Vice President of Technology at Innophos. “Magnesium gummies made with Chelamax® Magnesium Citrate also improve the texture and sensory experience of gummies, making them more appealing to consumers.”

Innophos offers a broad range of proven chelated minerals under the Chelamax® brand, including powder and granular forms. The company also provides technical support and formulation assistance to help customers optimize their gummy and other formulations. Innophos is committed to providing the highest quality, science-backed products, and raising the bar in the nutrition industry in terms of validation, transparency, and application development.

Download the complimentary Chelamax® whitepaper here.

Click here to learn more about how Chelamax® fully chelated minerals can help you get the most from your mineral supplements.    

About Innophos

Innophos is a leading international producer of specialty ingredient solutions that deliver far-reaching, versatile benefits for the food, health, nutrition, and industrial markets. We leverage our expertise in the science and technology of blending and formulating phosphate, mineral, and botanical based ingredients to help our customers offer products that are tasty, healthy, and nutritious. Headquartered in Cranbury, New Jersey, Innophos has manufacturing operations across the United States, in Canada, Mexico, and China. For more information, please visit http://www.innophos.com

Share article on social media or email: